All Episodes
GRACEcast — 599 episodes · page 2 of 6
Novel Immunotherapies and Combinations
Blood-Based Mutation Testing: Circulating Tumor Cells and Tumor DNA
Immunotherapy Biomarkers and Patient Selection
What Is Next-Gen Sequencing?
Immunotherapy for Melanoma
Immunotherapy for Lung Cancer
Immunotherapy for Genitourinary Cancers
The Patient Perspective
Immunotherapy for First Line Therapy of Advanced NSCLC
Managing Immunotherapy Side Effects
What is the Optimal Duration of Immunotherapy?
The Current Role of Immunotherapy in the Treatment of Patients with Cancer
Panel Q&A Session on Patient Access and Survivorship
What is Immunotherapy & Its Mechanisms of Action?
Living with Lung Cancer
Access & Assistance for ALK+, ROS1 & EGFR Patients
Panel Q&A Session on Sequencing EGFR Treatments with Drs. Riely and West
Treatment Options for EGFR T790M Negative Acquired Resistance
Emerging Options for T790M-Positive Acquired Resistance
Individual Treatments for Individual EGFR Mutations
Panel Q&A Session on ALK+ and ROS1 Acquired Resistance with Drs. Horn and Owonikoko
The Blood/Brain Barrier for ALK Patients
New Ideas and New Treatment Options for Acquired Resistance for ALK/ROS1
Panel Q&A Session on Acquired Resistance with Drs. Riely & Horn
What is the Role of Immunotherapy for Patients with Advanced NSCLC and a Driver Mutation?
Repeat Biopsies and Emerging Techniologies for Plasma Sampling of Mutations Seen with Acquired Resistance
Panel Q&A Session on Acquired Resistance with Drs. Reckamp & Owonikoko
Time to Response to Immunotherapy and the Concept of Pseudoprogression
Have Your Practices Changed Regarding Prophylactic Cranial Irradiation for Extensive Stage SCLC Patients?
How Important is the Impact of Smoking Cessation on Survival?
What Are Your Current Practices for Consolidation Chest Radiation for Extensive SCLC?
Are There Clinically Significant Differences Among the Third Generation EGFR Inhibitors?
What is Acquired Resistance to Targeted Therapy, and Why Does it Occur?
The Central Nervous System as a Sanctuary Site: The Special Case for Brain Metastases
Can or Will Specific Molecular Characteristics Help Determine Which ALK Inhibitor to Choose?
Are There Clinically Significant Differences Among the Second Generation ALK Inhibitors?
Can Patients Benefit from Broad vs. Focal Genetic Testing?
Does the Specific EGFR Mutation (Including "Rare" Mutations) Matter When Choosing an Oral EGFR Inhibitor?
What Are the Treatment Choices for EGFR Mutation-Positive Acquired Resistance in Patients Without a T790M Mutation?
Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?
Immunotherapy Combinations: Is this the Future for Treating Lung Cancer?
Should Third Generation EGFR Inhibitors Be Used Before First Generation EGFR TKIs or After Progression?
What Are You Grateful For?
The Lung Cancer Master Protocol/SWOG 1400 as a Clinical Trial for a New Era of Molecular Oncology
Clinical Trial Spotlight: Targeting Brain Mets in EGFR Lung Cancer Patients
In Sickness and In Health
Clinical Trial Spotlight: Can Epigenetic Priming Improve Efficacy of Immunotherapy in NSCLC?
Clinical Trial Spotlight: Identifying Lung Cancer Patients Who Respond to Ponatinib
Postcards from Her Patients
Clinical Trial Spotlight: Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance
Clinical Trials of Immune Checkpoint Inhibitors as FIrst Line Therapy for Advanced NSCLC
What is the Current Role of Serum Based Biomarker Testing?
Should Immune Checkpoint Inhibitors and Other Therapies Be Combined Concurrently or Sequentially?
Are Immune Checkpoint Inhibitors Sufficiently Tolerable to Recommend Them for Older or More Frail Patients?
Clinical Trial Spotlight: Should a Second Generation ALK Inhibitor be First Line Therapy for Patients with ALK-Positive NSCLC?
Is It Feasible and Clearly Beneficial to Combine Immunotherapy Approaches?
Do Clinical Characteristics Alter Your Enthusiasm for Immune Checkpoint inhibitors?
Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?
Should PD-L1 be Used as a Biomarker for Immunotherapy in Lung Cancer?
Should PD-L1 Testing Be Ordered at Diagnosis or After Progression?
Immunotherapy for Previously Treated Advanced Non-Small Cell Lung Cancer
Do You Order PD-L1 Testing Before Choosing an Immune Checkpoint Inhibitor?
Clinical Trial Spotlight: Determining Efficacy of Immunotherapy in Stage III Lung Cancer
Clinical Trial Spotlight: ALCHEMIST for Early-Stage ALK+ and EGFR Lung Cancer Patients
Are there Clinically Significant Differences Among Immune Checkpoint Inhibitors Treating Lung Cancer?
Here Today Thanks to Research
First Line Treatment of EGFR Mutation-Positive NSCLC
Promising Early Results with Immunotherapy for Mesothelioma
Grateful for Another Great Year
November is Lung Cancer Awareness Month
Is the Survival Benefit with Avastin Added to Chemotherapy Enough to Change the Standard of Care in Mesothelioma?
ECOG 1505 Study: No Benefit of Post-Operative Avastin in Early Stage Lung Cancer Patients
Immunotherapy for Lung Cancer: General Concepts
Should EGFR TKI Therapy be Continued Beyond Progression?
The Potential Value of Repeat Biopsies in Acquired Resistance
Patterns of Acquired Resistance to EGFR TKIs in EGFR Mutation-Positive NSCLC
Are There Distinctions Among Currently Available Oral EGFR Inhibitors for EGFR Mutation-Positive NSCLC?
Differences Among Specific EGFR Mutations
What is EGFR and the EGFR Mutation?
What is the Value of Testing for Molecular Markers in Advanced NSCLC?
Radiation Management of Limited Stage SCLC
Prophylactic Cranial Irradiation for Extensive Stage Small Cell Lung Cancer
Prophylactic Cranial Irradiation for Limited Stage Small Cell Lung Cancer
Should Avastin be Added to EGFR TKI Therapy for EGFR Mutation-Positive NSCLC?
What is Maintenance Therapy for Advanced NSCLC?
Optimal Systemic Therapy for Bronchioloalveolar Carcinoma (BAC)
Reirradiation of Tumor in a Previously Radiated Field
Cancer Growth Rate and Managing Slow-Growing Lung Cancers
What is a Pancoast Tumor and How is it Best Treated?
Basic Principles of Managing Locally Advanced NSCLC
Pre-Operative/Neoadjuvant Therapy: Rationale and Indications
Surgery Options for Smaller, Slow-Growing Lung Cancers
Immunotherapy for Kidney Cancer Patients in the Front-line Setting: Coming Soon?
Immunotherapy for Metastatic Kidney Cancer Shows Increased Survival
Stereotactic Body Radiation Therapy (SBRT) for Medically Inoperable Early Stage Lung Cancer
Special Considerations for Lung Cancer Surgery in the Elderly
Challenges of Pneumonectomy Surgery
Types of Lung Surgery: From Wedge Resection to Pneumonectomy
Defining TNM Staging and Early Stage NSCLC
Managing Malignant Pleural Effusions: Pleurodesis